January 23, 2026
World-First PGD Success Prevents Rare Genetic Disorder in Baby
A groundbreaking pre-implantation genetic diagnosis (PGD) procedure has successfully prevented the transmission of mucolipidosis, a rare inherited disorder, in a UK couple’s pregnancy, marking the first global case using karyomapping technology. The couple, with two children—one healthy and one severely affected—now has a baby due next month who will be unaffected by the disorder. The Waterstone Clinic’s karyomapping method offers rapid, cost-effective PGD testing for nearly any genetic condition.
Key Takeaways
Karyomapping Enables Rapid, Accurate PGD for Genetic Disorders
Karyomapping streamlines PGD testing by analyzing almost any known gene defect in two weeks, replacing costly, slow, and customized tests. This technology allows clinics to identify and transfer embryos free of inherited conditions like mucolipidosis, reducing risks for families with a history of genetic disorders.
PGD Treatment Costs €9,500–€12,000 with Limited Availability
The Waterstone Clinic charges €9,500 to €12,000 for PGD with karyomapping, a price described as ‘not more expensive’ than previous methods. Access is restricted to conditions like cystic fibrosis and muscular dystrophy, targeting life-limiting disorders where prevention is critical.
Previous Success in Cystic Fibrosis PGD Case Demonstrates Efficacy
Another couple at the clinic used karyomapping to conceive a baby free of cystic fibrosis despite both parents being carriers. This confirms the method’s effectiveness in preventing multiple genetic conditions, not just mucolipidosis.
World-First PGD for Mucolipidosis Averts Life-Threatening Condition
Mucolipidosis, a disorder causing severe growth failure and early death, is now preventable via PGD. The Waterstone Clinic’s achievement marks the first global application of karyomapping to this specific genetic defect, offering hope to families at risk.
PGD Screen Embryos to Transfer Only Unaffected Genes
The PGD process involves screening embryos for genetic mutations before implantation, ensuring only unaffected embryos are transferred. This eliminates the one-in-four risk of passing on recessive disorders like mucolipidosis, significantly improving pregnancy outcomes for carrier parents.
Source: Read full article